Technology

AtG Therapeutics’ technology is based on our unique ability to design and develop strategies that selectively target and eliminate cancer cells resistant to anti-angiogenic therapy

AtG can help when standard therapy fails

How it works

Determine plasma levels of RF-1 in metastatic kidney patients

Selection of patients with higher RF-1 levels

Treatment with RF-1 inhibitor

With our technology we will improve the lives of patients affected by cancer therapeutic resistance

Advantages

Fills a medical need

Fast prediction of patients response

New tool for clinical decision-making processes to be made regarding treatments.

Our technology could be applied to other tumors too

Pipeline

January 1, 2019

AtG 101
RF-1 Inhibitor

First-in-Class anti-cancer treatment to prevent anti-angiogenics resistance.

Development status:
HIT to LEAD

January 1, 2019
January 1, 2019

AtG 102
RF-1 Companion Dx

Diagnostic test to determine which patients will benefit from RF-1 inhibitor (AtG 101), thus delivering a more personalized treatment.

Development status:
Prototype

January 1, 2019
January 1, 2019

AtG 103
MF-1 Predictor

Diagnostic test to determine which patients will benefit from anti-angiogenic inhibitors, thus delivering a more personalized treatment.

Development status:
Discovery

January 1, 2019
January 1, 2019

AtG 153
RF-1 Inhibitor

First-in-Class anti-cancer treatment to prevent anti-angiogenics resistance.
Development status:
LEAD OPTIMIZATION

January 1, 2019